<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sparano, Joseph A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">AC and Weekly Paclitaxel Improve Outcomes in TNBC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-8</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents the 10-year results of a study comparing taxane type and schedule as a component of adjuvant chemotherapy in localized breast cancer. When administered after doxorubicin-cyclophosphamide, weekly paclitaxel and every-3-weeks docetaxel significantly improved outcomes in the entire study population, while weekly paclitaxel improved outcomes in triple-negative breast cancer.</style></abstract><number><style face="normal" font="default" size="100%">56</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>